Anti-IFNAR (Anifrolumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC
Anti-IFNAR (Anifrolumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (ADC-W-2059)
This ADC product is comprised of an anti-IFNAR monoclonal antibody conjugated via a MC-Vc-PAB-DMEA-(PEG2) linker to duocarmycin SA. The duocarmycin SA is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, duocarmycin SA binds to DNA, causes DNA damage.
ADC Target
Name
IFNAR
Alternative Names
IFNAR, interferon-α/β receptor
Overview
The interferon-α/β receptor (IFNAR) is a receptor which binds type I interferons including interferon-α and -β. It is a heteromeric receptor composed of one chain with two subunits referred to as IFNAR1 and IFNAR2. It is a cell surface receptor.
ADC Antibody
Overview
Human Anti-IFNAR IgG1-kappa antibody, Anifrolumab
Generic name
Anifrolumab
Host animal
Human
ADC Linker
Name
MC-Vc-PAB-DMEA-(PEG2)
Description
Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
ADC payload drug
Name
duocarmycin SA
Description
Duocarmycins SA belong to the minor-groove-binding DNA-alkylating agents (DNA MGBA). The natural duocarmycins are isolated from the culture broth of Streptmyces sp and a series of derivatives has also been synthesized.